Mesa Laboratories Reports First Quarter Fiscal 2026 Results

MESA LABORATORIES INC /CO/

2025-Q1 EPS reported $0.85 revenue$59,543,000

Total revenues increased 2.4% to $59,543,000 for the quarter ended June 30, 2025.
Operating income decreased 45.1% to $3,064,000, impacted by FX and stock-based compensation.
Clinical Genomics division revenue fell 10.7% core organic as China revenues contracted 69%.
About $1.5M of expected Biopharmaceutical Development revenues shifted from Q1 to Q2 due to tariff surcharges.
Non-GAAP adjusted operating income (excluding unusual items) was $12,902, down 15.9% year-over-year.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.